Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors<\/p>\n
September 30, 2019<\/p>\n
LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Dr. David Wheadon
\nhas been appointed to the Company\u2019s Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc.
\n\u201cDavid is a globally recognized leader in healthcare and we are thrilled to have him join our Board of Directors,\u201d said Arthur Higgins, President and
\nCEO of Assertio. \u201cDavid\u2019s perspectives, both as a physician and as an executive with significant and broad industry expertise, will add further depth
\nand breadth to our Board.\u201d<\/p>\n
\u201cI am excited to serve on Assertio\u2019s Board and contribute to its ongoing transformation into a leading diversified biopharmaceutical company,\u201d said Dr.
\nWheadon.<\/p>\n
Dr. Wheadon is a former senior executive of AstraZeneca plc, having recently retired as Senior Vice President, Global Regulatory Affairs, Patient
\nSafety and Quality Assurance. Dr. Wheadon has held many leadership roles in the healthcare sector, including: Executive Vice President, Research
\nand Advocacy at the Juvenile Diabetes Research Foundation; Senior Vice President, Scientific and Regulatory Affairs at PhRMA; Senior Vice
\nPresident of Global Pharmaceutical Regulatory and Medical Sciences at Abbott Laboratories; Senior Vice President of U.S. Regulatory Affairs at
\nGlaxoSmithKline Pharmaceuticals; Vice President and Director CNS\/GI Clinical Research at SmithKline Beecham Pharmaceuticals; and Clinical
\nResearch Physician at Eli Lilly and Company. Dr. Wheadon has been integral to the successful development and approval of several important drugs
\nfor central nervous system diseases, diabetes, gastrointestinal disorders and diseases in other therapeutic areas.<\/p>\n
Dr. Wheadon holds a M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his
\npostdoctoral training in Psychiatry at Tufts\/New England Medical Center in Boston, Massachusetts.<\/p>\n
About Assertio Therapeutics, Inc.<\/em><\/p>\n Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company\u2019s core areas of neurology, orphan and “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995<\/em><\/p>\n This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to <\/p>\n Investor and Media Contact:<\/em><\/p>\n John B. Thomas Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors September 30, 2019 LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Dr. David Wheadon has been appointed to the Company\u2019s Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc. […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"footnotes":""},"categories":[103],"tags":[109],"class_list":["post-2435","post","type-post","status-publish","format-standard","hentry","category-newscat","tag-news"],"acf":[],"yoast_head":"\n
\nspecialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer
\nenhanced options for patients that may be underserved by existing therapies. To learn more about Assertio, visit www.assertiotx.com.<\/p>\n
\ndiffer materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange
\nCommission, including the Company’s most recent annual report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All information
\nprovided in this news release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or
\nrevise its forward-looking statements.<\/p>\n
\nSVP, Investor Relations and Corporate Communications
\njthomas@assertiotx.com<\/p>\n","protected":false},"excerpt":{"rendered":"